Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NEA and Venrock take part in $15mm Acadia financing

Executive Summary

New Enterprise Associates and Venrock were part of a group of backers that invested $15mm in Acadia Pharmaceuticals Inc. (developing neurological and glaucoma medicines). The company sold 12.57mm shares at $1.19 (market average) plus warrants to buy another 4.4mm shares. JMP Securities and MTS Securities were the placement agents. The proceeds, which give Acadia enough cash into 2013, will pay for Phase III trials of lead candidate pimavanserin, a 5-HT2A antagonist for Parkinson’s disease psychosis. Two months ago, Acadia lost Biovail (now Valeant) as its partner for the project.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register